Albireo to Participate in Jefferies London Healthcare Conference
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022. Simon Harford, Chief Financial Officer of Albireo, will be presenting on November 15, 2022, at 10:20 AM GMT.
A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo's lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome (ALGS), an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contacts:
Colleen Alabiso, 857-356-3905, [email protected]
Lance Buckley, 917-439-2241, [email protected]
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
